We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MeiraGTx

News List

Janssen/MeiraGTx sight loss gene therapy hits targets pharmatimes
July 21, 2020
Janssen has unveiled six-month data from an ongoing Phase I/II trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP).
MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate biospace
March 05, 2018
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe
MeiraGTx obtains rare disease designation for gene therapy A001 pharmaceutical-technology
December 12, 2017
Gene Therapy Developer MeiraGTx Receives Outstanding Pediatric Disease Title from the U.S. Food and Drug Administration (FDA)